已知癌基因和抑癌基因的突变或异常表达会导致癌症。最近的研究表明，表观遗传修饰是癌症发生和进展的关键驱动因素。然而，肿瘤微环境中表观遗传失调的机制作用尚不完全清楚。本文综述了肿瘤微环境中癌细胞和非癌细胞表观遗传修饰的作用以及癌症表观遗传药物的最新研究进展。此外，我们还讨论了表观遗传联合疗法在癌症临床治疗中的巨大潜力。然而，癌症表观遗传学领域仍存在一些挑战，如表观遗传学肿瘤异质性、表观遗传学药物异质性以及表观遗传学与蛋白质组学、代谢组学等组学之间的串扰，这些可能是未来癌症治疗的重点和难点。总之，肿瘤微环境的表观遗传修饰对于未来表观遗传药物的开发和癌症的综合治疗至关重要。表观遗传联合疗法可能是未来癌症临床治疗的一种新策略。© 2023 作者。 Elsevier B.V. 代表科爱通讯有限公司提供的出版服务

Mutations or abnormal expression of oncogenes and tumor suppressor genes are known to cause cancer. Recent studies have shown that epigenetic modifications are key drivers of cancer development and progression. Nevertheless, the mechanistic role of epigenetic dysregulation in the tumor microenvironment is not fully understood. Here, we reviewed the role of epigenetic modifications of cancer cells and non-cancer cells in the tumor microenvironment and recent research advances in cancer epigenetic drugs. In addition, we discussed the great potential of epigenetic combination therapies in the clinical treatment of cancer. However, there are still some challenges in the field of cancer epigenetics, such as epigenetic tumor heterogeneity, epigenetic drug heterogeneity, and crosstalk between epigenetics, proteomics, metabolomics, and other omics, which may be the focus and difficulty of cancer treatment in the future. In conclusion, epigenetic modifications in the tumor microenvironment are essential for future epigenetic drug development and the comprehensive treatment of cancer. Epigenetic combination therapy may be a novel strategy for the future clinical treatment of cancer.© 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.